Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Presse Medicale (Paris, France : 1983)|April 23, 2013
[Use of drug reimbursement as markers of disease for epidemiological and cost analysis: The case of severe epilepsy in France]Francis Fagnani, Hervé Vespignani, Odile Kusnik-Joinville, et al.
Therapie|June 3, 2005
[Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat]Muriel Vray, Jean-Michel Joubert, Eveline Eschwège, et al.
Therapie|March 26, 2005
[Methodology and quality control in EPIGRAM, a pharmacoepidemiological study of obesity in general practice]Muriel Vray, Jean-Michel Joubert, Eveline Eschwège, et al.
Joint Bone Spine|May 1, 2018
Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and costPascal Claudepierre, Francis Fagnani, Gabrielle Cukierman, et al.
Journal of Medical Economics|April 12, 2016
Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in FranceFrancis Fagnani, Thao Pham, Pascal Claudepierre, et al.
Journal of Medical Economics|March 6, 2019
Migraine burden and costs in France: a nationwide claims database analysis of triptan usersAnne Donnet, Corinne Emery, Samia Aly, et al.
RMD Open|January 21, 2020
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational studyAlain Saraux, René-Marc Flipo, Francis Fagnani, et al.
Joint Bone Spine|August 2, 2015
Impact of rheumatoid arthritis on career progression, productivity, and employability: The PRET StudyPhilippe Bertin, Francis Fagnani, Anne Duburcq, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR studyAlain Saraux, Bernard Combe, Francis Fagnani, et al.
Antiviral Therapy|January 24, 2012
Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007)Marc Bourlière, Denis Ouzan, Michel Rosenheim, et al.
Pageof 5